Orion Oyj (ORINF)
82.75
0.00 (0.00%)
USD |
OTCM |
Aug 25, 16:00
Orion Net Income (Quarterly) : 163.01M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 163.01M |
| March 31, 2026 | 105.76M |
| December 31, 2025 | 303.20M |
| September 30, 2025 | 112.19M |
| June 30, 2025 | 93.58M |
| March 31, 2025 | 64.52M |
| December 31, 2024 | 78.30M |
| September 30, 2024 | 176.65M |
| June 30, 2024 | 55.98M |
| March 31, 2024 | 47.54M |
| December 31, 2023 | 80.76M |
| September 30, 2023 | 66.79M |
| June 30, 2023 | 39.62M |
| March 31, 2023 | 46.99M |
| December 31, 2022 | 32.34M |
| September 30, 2022 | 195.81M |
| June 30, 2022 | 70.35M |
| March 31, 2022 | 64.28M |
| December 31, 2021 | 37.49M |
| September 30, 2021 | 53.51M |
| June 30, 2021 | 67.52M |
| March 31, 2021 | 71.79M |
| December 31, 2020 | 30.40M |
| September 30, 2020 | 60.08M |
| June 30, 2020 | 83.26M |
| Date | Value |
|---|---|
| March 31, 2020 | 74.25M |
| December 31, 2019 | 50.04M |
| September 30, 2019 | 79.61M |
| June 30, 2019 | 45.84M |
| March 31, 2019 | 48.60M |
| December 31, 2018 | 61.28M |
| September 30, 2018 | 39.90M |
| June 30, 2018 | 66.21M |
| March 31, 2018 | 66.00M |
| December 31, 2017 | 64.05M |
| September 30, 2017 | 50.00M |
| June 30, 2017 | 60.86M |
| March 31, 2017 | 71.20M |
| December 31, 2016 | 51.30M |
| September 30, 2016 | 80.92M |
| June 30, 2016 | 74.18M |
| March 31, 2016 | 69.79M |
| December 31, 2015 | 43.12M |
| September 30, 2015 | 50.35M |
| June 30, 2015 | 63.83M |
| March 31, 2015 | 73.86M |
| December 31, 2014 | 50.97M |
| September 30, 2014 | 65.98M |
| June 30, 2014 | 93.25M |
| March 31, 2014 | 72.07M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| AstraZeneca PLC | 3.076B |
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 42.14M |
| Veru, Inc. | -6.988M |
| Avadel Pharmaceuticals Plc | 0.02M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 606.47M |
| Total Expenses (Quarterly) | 443.46M |
| EPS Diluted (Quarterly) | 1.157 |
| Enterprise Value | 11.66B |
| Gross Profit Margin (Quarterly) | 65.16% |
| Profit Margin (Quarterly) | 26.88% |
| Earnings Yield | 5.87% |
| Operating Earnings Yield | 7.40% |
| Normalized Earnings Yield | 5.875 |